Boston, MA, USA, and London, United Kingdom

December 22, 2020

Signifier Medical Technologies (“Signifier” or “the Company”), an innovator in the sleep disordered breathing market, is pleased to announce the successful award of the UK Non-invasive Ventilation, Sleep Therapy and Sleep Monitoring Tender, which will confirm Signifier as an approved supplier to the UK’s National Health Service (NHS).

This contract award gives Signifier direct access to the NHS supply chain, including the relevant coding, inventory and ordering systems, to enter the important UK NHS market. Yasser Zayni, Signifier’s Regulatory & Quality Director, was instrumental in the process and commented that “this award will help to accelerate patient access to our innovative technology across the UK.”

eXciteOSA® is the only clinically proven daytime intraoral neuromuscular stimulation device to improve the quality of sleep by reducing sleep apnea and snoring significantly when used for 20 minutes once a day for six weeks1-4. The device has been designed to treat a wide range of patients with mild obstructive sleep apnea (OSA), in addition to primary snoring, by building endurance of the weak tongue and surrounding muscles known to be root causes of these conditions.

Signifier has also focused on digital OSA therapy interfaces for patients and clinicians. An intuitive app for use alongside the eXciteOSA device motivates a patient to achieve high treatment compliance and to monitor progress. In addition, therapy data is available on Signifier’s clinician portal, enabling the medical community to monitor and track results.

With European CE Mark approval, the Company is planning for wider expansion to support the commercialization and reimbursement of eXciteOSA in the UK, Germany and other major European markets. The Company has also established its US office in Boston and is building commercial operations there ahead of the anticipated approval and launch of eXciteOSA in the important US market.

Akhil Tripathi, CEO of Signifier, commented: “The light touch nature of eXciteOSA and its digital user interface and companion app means that it is a product ideally suited to current times. The award of this NHS contract reflects the hard work and commitment of our employees and is an important pillar of our commercial launch strategy, which will focus on HCPs (Health Care Professionals). We have a unique product backed by excellent clinical data, which we believe can make a significant difference to the lives of many patients suffering from sleep disordered breathing conditions and we look forward to bringing this product to patients more widely.”

For more information, please contact:

Signifier Medical Technologies
Email: info@signifiermedical.com
Tel: +44 (0)20 7096 0586

About Signifier Medical Technologies

Signifier Medical Technologies is a medical technology company focused on the development and commercialization of innovative and non-invasive solutions for patients with sleep-disordered breathing conditions and snoring.

Signifier’s proprietary therapy eXciteOSA® is the first and only daytime genioglossal (tongue) muscle-neurostimulation technology for mild obstructive sleep apnea and snoring, supported by clinical data from prestigious and well-recognized universities and academic institutions, that provides a safe and effective treatment for its patients.^1-3

About OSA and Snoring

Nearly 1 billion adults aged 30 to 69 years are estimated to have obstructive sleep apnea (OSA) globally. There is a strong, clinically proven link between OSA and co-morbidities like diabetes, hypertension, and strokes. Mild OSA affects over 110 million people in the US and 100 million people in Europe.

Obstructive sleep apnea is marked by the recurring collapse of the upper airways during sleep. The most common symptoms are restless sleep, snoring, tiredness during the day, decreased intellectual alertness, and personality alterations. Higher risks of cardiovascular diseases and increased mortality rates have been associated with OSA.

Standard therapy of all advanced levels of sleep apnea is with a continuous positive airway pressure (CPAP) device. Many patients find this therapy invasive, and the long-term compliance of CPAP therapy is limited, so there is a clear demand for new forms of treatment.

References

1. White DP. Sleep-related breathing disorder: 2—pathophysiology of obstructive sleep apnoea. Thorax. 1995; 50:797–804. [PubMed: 7570420]

2. Wessolleck E, Bernd E, Dockter S, et al. Intraoral electrical muscle stimulation in the treatment of snoring. Somnologie (Berl). 2018; 22 (Suppl 2): 47–52.

3. Sama A, et al. Daytime Intraoral Neurostimulation with Snoozeal® for Treatment of Snoring and Mild Sleep Apnea. CHEST Annual Meeting Notes. 2018.

4. Clinical study of 115 patients with snoring or mild OSA (Apnea- Hypopnea Index (AHI <15 n=65). Objective snoring and respiratory parameters were recorded with 2 consecutive WatchPat night sleep studies before and after the use of the device. An intra-oral tongue stimulator (Snoozeal®) device was used for 20mins, once a day for 6-week period

Boston, MA, USA, and London, United Kingdom

November 24, 2020

Signifier Medical Technologies (“Signifier/the Company”), an innovator in the sleep-disordered breathing market, is pleased to announce the appointment of Alastair Maxwell as Chief Financial Officer with immediate effect. He will be based in Boston and London and will be responsible for all aspects of the Company’s financial strategy, management, and operations including ensuring that the Company is adequately financed to meet its ambitious growth plans.

Mr. Maxwell has enjoyed a long and successful career in the investment banking industry where he worked for almost 30 years. This was most recently with Goldman Sachs from 2010 to 2016 where he was a Partner and Global Industry Group Co-Head with responsibility for relationships with a wide range of corporate and other clients.

Previous to this, he was with Morgan Stanley, most recently as Managing Director and Industry Head in the EMEA region, and prior to that with Dresdner Kleinwort Benson.

Prior to joining Signifier, Mr. Maxwell was Chief Financial Officer at NYSE-listed companies GasLog Ltd and GasLog Partners LP where he worked closely with the Board and senior management team to facilitate the growth of the business and to secure the funding required to support this growth.

During his career, Mr. Maxwell has been involved in a wide range of strategic and financing transactions, including equity, equity-linked, bond and bank financings for a variety of private and public companies.

Akhil Tripathi, CEO of Signifier commented: “This latest key appointment further rounds out our world-class leadership team. Alastair brings significant expertise to the Company in capital markets, fundraising, and corporate strategy. His global and US experience will be crucial in supporting Signifier and ensuring that we have access to the appropriate financing as we seek to rapidly expand our business.”

Alastair Maxwell added: “I am excited to be joining Signifier at this important time in its development. With the anticipated launch of eXciteOSA®, the Company is poised for significant growth. I look forward to utilizing my skills and network to work with Akhil and the rest of the team to help the Company realize its tremendous potential.”

For more information, please contact:

Signifier Medical Technologies
Email: info@signifiermedical.com
Tel: +44 (0)20 7096 0586

About Signifier Medical Technologies

Signifier Medical Technologies is a medical technology company focused on the development and commercialization of innovative and non-invasive solutions for patients with sleep-disordered breathing conditions and snoring.

Signifier’s proprietary therapy eXciteOSA® is the first and only daytime genioglossal (tongue) muscle-neurostimulation technology for mild obstructive sleep apnea and snoring, supported by clinical data from prestigious and well-recognized universities and academic institutions, that provides a safe and effective treatment for its patients.^1-3

About OSA and Snoring

Nearly 1 billion adults aged 30 to 69 years are estimated to have obstructive sleep apnea (OSA) globally. There is a strong, clinically proven link between OSA and co-morbidities like diabetes, hypertension, and strokes. Mild OSA affects over 110 million people in the US and 100 million people in Europe.

Obstructive sleep apnea is marked by the recurring collapse of the upper airways during sleep. The most common symptoms are restless sleep, snoring, tiredness during the day, decreased intellectual alertness, and personality alterations. Higher risks of cardiovascular diseases and increased mortality rates have been associated with OSA.

Standard therapy of all advanced levels of sleep apnea is with a continuous positive airway pressure (CPAP) device. Many patients find this therapy invasive, and the long-term compliance of CPAP therapy is limited, so there is a clear demand for new forms of treatment.

References

1. White DP. Sleep-related breathing disorder: 2—pathophysiology of obstructive sleep apnoea. Thorax. 1995; 50:797–804. [PubMed: 7570420]

2. Wessolleck E, Bernd E, Dockter S, et al. Intraoral electrical muscle stimulation in the treatment of snoring. Somnologie (Berl). 2018; 22 (Suppl 2): 47–52.

3. Sama A, et al. Daytime Intraoral Neurostimulation with Snoozeal® for Treatment of Snoring and Mild Sleep Apnea. CHEST Annual Meeting Notes. 2018.

4. Clinical study of 115 patients with snoring or mild OSA (Apnea- Hypopnea Index (AHI <15 n=65). Objective snoring and respiratory parameters were recorded with 2 consecutive WatchPat night sleep studies before and after the use of the device. An intra-oral tongue stimulator (Snoozeal®) device was used for 20mins, once a day for 6-week period

Boston, MA, USA and London, United Kingdom

October 08, 2020

Senior appointment in preparation for commercialization in markets outside the USA of eXciteOSA®, a novel, non-invasive, daytime therapy for sleep-disordered breathing conditions

Signifier Medical Technologies (“Signifier”), an innovator in the sleep-disordered breathing market, is pleased to announce the appointment of Travis Nieman as Managing Director International. Mr. Nieman joins the company from Stryker where he was Managing Director International & Global Reimbursement, Stryker Ear Nose & Throat. He will be responsible for the commercial development of eXciteOSA® in all markets outside the USA.

Mr Nieman is a highly experienced commercial leader in healthcare with a proven track record in small and large organizations over more than 20 years. Prior to Stryker, he was a Director of International Marketing at Baxter and before that spent several years at Medtronic as Brand Manager Europe-Central Asia. Mr. Nieman began his career at The Coca-Cola Company.

Akhil Tripathi, CEO of Signifier commented: “We are very pleased to welcome Travis as the newest member of our senior management team. His skills and experience in healthcare device management, developing and launching new technologies, health economics outcomes research and market access, business development, and commercial leadership will be invaluable in driving the commercial strategy for eXciteOSA^® in international markets outside of the US. His appointment represents another key building block in our mission to bring our novel technology to markets globally.”

Travis Nieman added: “eXciteOSA^® is a highly innovative product and I believe represents a unique opportunity to improve the lives of many patients suffering from sleep-disordered breathing. We intend to build a seamless pathway for users including an integrated digital strategy that offers the potential to bring broader healthcare benefits to patients. I look forward to bringing my skills and experience to bear at Signifier Medical as we continue on this exciting phase of our journey over the next 12 months and beyond.”

Mr Nieman’s appointment further expands the senior management team. In September, Signifier announced the appointment of Philip Hess, former President and CEO of Bose Corporation, as Chief Operating Officer based in Boston, USA, where Signifier is establishing its US operations. In July, Signifier announced the appointment of Mr. Matt Sharris as Vice President of Sales for North America. We look forward to announcing further key appointments as we build out our world-class leadership team.

For more information, please contact:

Signifier Medical
Email: info@signifiermedical.com
Tel: +44 (0)20 7096 0586

About Signifier Medical Technologies

Signifier Medical Technologies is a medical technology company focused on the development and commercialization of innovative and non-invasive solutions for patients with snoring and sleep-disordered breathing conditions.

Signifier’s proprietary therapy eXciteOSA® is the first and only daytime genioglossal (tongue) muscle-neurostimulation technology for snoring and mild obstructive sleep apnea, supported by clinical data from prestigious and well-recognized universities and academic institutions, that provides a safe and effective treatment for its patients.^1-3

About Snoring and OSA

Nearly 1 billion adults aged 30 to 69 years are estimated to have obstructive sleep apnea (OSA) globally. There is a strong, clinically proven link between OSA and co-morbidities like diabetes, hypertension, and strokes. Mild OSA affects over 110 million people in the US and 100 million people in Europe.

Obstructive sleep apnea is marked by the recurring collapse of the upper airways during sleep. The most common symptoms are restless sleep, snoring, tiredness during the day, decreased intellectual alertness, and personality alterations. Higher risks of cardiovascular diseases and increased mortality rates have been associated with OSA.

Standard therapy of all advanced levels of sleep apnea is with a continuous positive airway pressure (CPAP) device. Many patients find this therapy invasive, and the long-term compliance of CPAP therapy is limited, so there is a clear demand for new forms of treatment.

References

1. White DP. Sleep-related breathing disorder: 2—pathophysiology of obstructive sleep apnoea. Thorax. 1995; 50:797–804. [PubMed: 7570420]
2. Wessolleck E, Bernd E, Dockter S, et al. Intraoral electrical muscle stimulation in the treatment of snoring. Somnologie (Berl). 2018; 22 (Suppl 2): 47–52.
3. Sama A, et al. Daytime Intraoral Neurostimulation with Snoozeal® for Treatment of Snoring and Mild Sleep Apnea. CHEST Annual Meeting Notes. 2018.
4. Clinical study of 115 patients with snoring or mild OSA (Apnea- Hypopnea Index (AHI <15 n=65). Objective snoring and respiratory parameters were recorded with 2 consecutive WatchPat night sleep studies before and after the use of the device. An intra-oral tongue stimulator (Snoozeal®) device was used for 20mins, once a day for 6-week period

London, United Kingdom

September 17, 2020

Signifier® Medical Technologies, an innovator in the sleep-disordered breathing market is delighted to announce that it has been awarded a bronze IDEA award by the prestigious Industrial Designers Society of America (IDSA) in the “Medical & Health” category, for its novel medical device, eXciteOSA^® – designed for patients with sleep-disordered breathing conditions.

Founded in 1965, Industrial Designers Society of America is one of the oldest and largest industrial design associations in existence, with 2020 marking the 40th anniversary of the International Design Excellence Awards (IDEA).

Originally founded to recognize exceptional achievement in industrial design, the program has since grown with thousands of entries submitted by design teams across the globe, making IDEA one of the largest and most widely anticipated annual awards programs in the world.

Professor Dr Anshul Sama (FRCS), Founder and Chief Medical Officer of Signifier Medical Technologies and Ear, Nose and Throat Surgeon at the University of Nottingham, was keenly aware of the fact that many of his patients were struggling with conventional treatment options for their sleep-disordered breathing (SDB) conditions. Based on an understanding of this significant unmet need and working with a talented multidisciplinary team, he created the world’s first, daytime treatment device that tackles the root cause of SDB.

eXciteOSA^® works by improving tongue muscle endurance and responsiveness preventing upper airway collapse during sleep. Clinically significant results have been observed, when used for 20 minutes, once a day, for 6 weeks. ^1-3

More information about the eXciteOSA^® IDSA award can be found here: https://www.idsa.org/awards/idea/medical-health/snoozeal

Images of the eXciteOSA^® device are available upon request to info@signifiermedical.com

About Snoring and OSA

Nearly 1 billion adults aged 30 to 69 are estimated to have obstructive sleep apnea (OSA) globally. There is a strong, clinically proven link between obstructive sleep apnea and co-morbidities like diabetes, hypertension, and strokes. Mild OSA affects over 110 million people in the US and 100 million people in Europe.¹

Obstructive sleep apnea is marked by the recurring collapse of the upper airways during sleep. The most common symptoms are restless sleep, snoring, tiredness during the day, decreased intellectual alertness and personality alterations. Higher risks of cardiovascular diseases and increased mortality rates have been associated with OSA.

About Signifier Medical Technologies

Signifier Medical Technologies is a medical technology company focused on the development and commercialization of innovative and non-invasive solutions for patients with snoring and sleep-disordered breathing conditions. Signifier’s proprietary therapy is the first and only daytime genioglossal (tongue) muscle-neurostimulation technology, with proven clinical data from prestigious and well-recognised universities and academic institutions, that provides a safe and effective therapy for patients.^2-4

About International Designers Society of America

Founded in 1965, IDSA is one of the oldest and largest membership associations for industrial design professionals with thousands of members in Student Chapters, Professional Chapters and Special Interest Sections in the United States and internationally. IDSA sponsors IDEA®, the world’s most prestigious and rigorous design competition. The Society hosts events including an annual International Design Conference, five District Design Conferences and a Medical Design Conference, bringing together some of the biggest names and brightest minds in industrial design and related fields.

References

1. White DP. Sleep-related breathing disorder: 2—pathophysiology of obstructive sleep apnoea. Thorax. 1995; 50:797–804. [PubMed: 7570420]
2. Wessolleck E, Bernd E, Dockter S, et al. Intraoral electrical muscle stimulation in the treatment of snoring. Somnologie (Berl). 2018; 22 (Suppl 2): 47–52.
3. Sama A, et al. Daytime Intraoral Neurostimulation with Snoozeal® for Treatment of Snoring and Mild Sleep Apnea. CHEST Annual Meeting Notes. 2018.
4. Clinical study of 115 patients with snoring or mild OSA (Apnea- Hypopnea Index (AHI <15 n=65). Objective snoring and respiratory parameters were recorded with 2 consecutive WatchPat night sleep studies before and after the use of the device. An intra-oral tongue stimulator (Snoozeal®) device was used for 20mins, once a day for 6-week period

For media enquiries:
info@signifiermedical.com
+44 (0) 207 096 0586

LONDON, 3^rd September 2020

Signifier Medical Technologies, an innovator in the sleep disordered breathing market, recently hosted a global webinar with leading world experts in the field of sleep disordered breathing (SDB).

The webinar was centred on “Precision Medicine and Non-Invasive Therapies for Mild Obstructive Sleep Apnea” and it was hosted by Prof. Dr. Adrian Williams (Professor of Sleep Medicine & Consultant Respiratory Physician, a founding member of the Sleep Section of the Royal Society of Medicine) and Prof. Dr. Atul Malhotra, (Research Chief in Pulmonary, Critical Care and Sleep Medicine at UC San Diego, USA).

Prof. Dr. Anshul Sama (Consultant ENT and Sleep Physician at Nottingham University Hospital, UK and inventor of the daytime intraoral neuromuscular electrical stimulation (NMES) technology^1-2 for reduction of sleep disordered breathing) also participated in the webinar presenting the technology and the new therapy options provided by NMES.

The webinar shed light on the SDB space, current treatment modalities, and presented the mechanism of action and clinical data on the new NMES technology.

eXciteOSA^® is a non-invasive daytime therapy for the tongue which delivers small contractions that improves muscle function and reduces the physiological collapse of the tongue during sleep. The device is a one size fits all and effective when used for 20 minutes a day for six weeks, with sustained improvement with minimal weekly maintenance.

Patients often find conventional night-time solutions for SDB ineffective or difficult to tolerate. With increasing public awareness of sleep related issues, and sleep therapy devices, it is increasingly likely that more patients will be consulting their healthcare professional on the therapy options available to them.

eXciteOSA^® gives healthcare professionals and patients an effective therapy that is easy and convenient to use.

If you missed it live, visit www.exciteosa.com/past-webinars to view previous webinars on-demand and register for future webinars.

About Snoring and OSA

Nearly 1 billion adults aged 30 to 69 are estimated to have obstructive sleep apnea (OSA) globally. There is a strong, clinically proven link between obstructive sleep apnea and co-morbidities like diabetes, hypertension, and strokes. Mild OSA affects over 110 million people in the US and 100 million people in Europe.

Obstructive sleep apnea is marked by the recurring collapse of the upper airways during sleep. The most common symptoms are restless sleep, snoring, tiredness during the day, decreased intellectual alertness and personality alterations. Higher risks of cardiovascular diseases and increased mortality rates have been associated with OSA.

Standard therapy of all advanced levels of sleep apnea is with a continuous positive airway pressure (CPAP) device. Many patients find this therapy invasive, and the long-term compliance of CPAP therapy can be limited, so there is a demand for new and innovative approaches.

About Signifier Medical Technologies

Signifier Medical Technologies is a medical technology company focused on the development and commercialization of innovative and non-invasive solutions for patients with snoring and sleep disordered breathing conditions. Signifier’s proprietary therapy is the first and only daytime genioglossal (tongue) muscle-neurostimulation technology, with proven clinical data from prestigious and well-recognised universities and academic institutions, that provides a safe and effective therapy for patients.^1-3

References

1. Wessolleck E, Bernd E, Dockter S, et al. Intraoral electrical muscle stimulation in the treatment of snoring. Somnologie (Berl). 2018; 22 (Suppl 2): 47–52.
2. Sama A, et al. Daytime Intraoral Neurostimulation with Snoozeal® for Treatment of Snoring and Mild Sleep Apnea. CHEST Annual Meeting Notes. 2018.
3. Clinical study of 115 patients with snoring or mild OSA (Apnea- Hypopnea Index (AHI <15). Objective snoring and respiratory parameters were recorded with 2 consecutive WatchPat night sleep studies before and after the use of the device. An intra-oral tongue stimulator (Snoozeal®) device was used for 20mins, once a day for 6-week period

For media enquiries:
info@signifiermedical.com
+44 (0) 207 096 0586

London, United Kingdom

September 02, 2020

Senior appointment in the US paves the way for the creation of USA operations in preparation for commercialisation of eXciteOSA®, a novel, non-invasive, daytime therapies for sleep-disordered breathing conditions.

Signifier Medical Technologies (“Signifier”), an innovator in the sleep-disordered breathing market, is pleased to announce the appointment of Philip Hess as Chief Operating Officer.

Mr. Hess is the former President & CEO of Bose Corporation, where he worked for 24 years across multiple leadership and operational roles. During his tenure, Mr. Hess was instrumental in Bose’s evolution from a speaker and DVD company to a leader in headsets and wireless products. Most recently, he was leading Bose into connected wearables and health products. He will be located in Boston, MA, where he will have responsibility for growing Signifier’s US infrastructure in preparation for the commercialisation of the company’s products.

Mr. Hess will additionally lead the formation of a new R&D function to identify and leverage innovative science to create new product opportunities for Signifier, aimed at improving the lives of the millions of people with sleep-disordered breathing conditions.

“With Signifier’s clinically-proven technology, we have the opportunity to treat several kinds of sleep disorders in a way never before possible” said Phil Hess. “Sleep is one of the core pillars of health. I’m incredibly excited to be part of a team that will improve the quality of life for millions of people.”

“I am delighted to welcome Phil to the company. He brings a valuable combination of skills and experience that we believe will benefit Signifier not only in the near-term, as we continue the global commercialisation of eXciteOSA®, but also in the future as we seek to build a global innovation-led healthcare company,” added Akhil Tripathi, CEO, and Co-Founder of Signifier Medical Technologies. “Phil is a key partner of this growth strategy. With other recent important appointments in the US and Europe, we are building a highly capable global team to deliver on our ambitions.”

In July, Signifier Medical Technologies announced the appointment of Mr. Matt Sharris as Vice President of Sales for North America. Matt brings strategic and commercial experience in respiratory and medical technologies and this follows the company strategy to drive and maximise the commercial footprint.

For more information, please contact:
Signifier Medical
Email: info@signifiermedical.com
Tel: +44 (0)20 7096 0586
Citigate Dewe Rogerson

Frazer Hall/Mark Swallow
Email: signifiermedical@citigatedewerogerson.com
Tel: +44 (0)20 7638 9571

Notes to Editors

About Signifier Medical Technologies

Signifier Medical Technologies is a medical technology company focused on the development and commercialisation of innovative and non-invasive solutions for patients with snoring and sleep-disordered breathing conditions.

Signifier’s proprietary therapy is the first and only daytime genioglossal (tongue) muscle-neurostimulation technology for snoring and mild obstructive sleep apnea, supported by clinical data from prestigious and well-recognised universities and academic institutions, that provides a safe and effective treatment for its patients.^1-3

For more information, please visit www.signifiermedical.com.

About Snoring and OSA

Nearly 1 billion adults aged 30 to 69 years are estimated to have obstructive sleep apnea (OSA) globally. There is a strong, clinically proven link between OSA and co-morbidities like diabetes, hypertension, and strokes. Mild OSA affects over 110 million people in the US and 100 million people in Europe.

Obstructive sleep apnea is marked by the recurring collapse of the upper airways during sleep. The most common symptoms are restless sleep, snoring, tiredness during the day, decreased intellectual alertness, and personality alterations. Higher risks of cardiovascular diseases and increased mortality rates have been associated with OSA.

Standard therapy of all advanced levels of sleep apnea is with a continuous positive airway pressure (CPAP) device. Many patients find this therapy invasive, and the long-term compliance of CPAP therapy is limited, so there is a clear demand for new forms of treatment.

SOURCE Signifier Medical Technologies

Related Links

www.signifiermedical.com
www.prnewswire.com

LONDON, 30th July 2020

Signifier Medical Technologies today announced that it will host a live webinar on Monday 1st September 7-8 pm BST to learn about the latest advances in the management of sleep disordered breathing and emerging new technologies in the field of sleep medicine.

Nearly 1 billion adults aged 30 to 69 are estimated to have obstructive sleep apnea (OSA) globally. There is a strong, clinically proven link between obstructive sleep apnea and co-morbidities like diabetes, hypertension, and strokes. Mild OSA affects over 110 million people in the US and 100 million people in Europe.

The webinar will feature three experts on sleep disordered breathing, Prof. Dr. Adrian Williams, Professor of Sleep Medicine & Consultant Respiratory Physician, a founding member of the Sleep Section of the Royal Society of Medicine, as well as having been awarded the UK’s first Chair in Sleep Medicine, and Prof. Dr. Atul Malhotra – Research Chief in Pulmonary, critical care and sleep medicine at UC San Diego. He is Peter C. Farrell Presidential chair and Professor in Respiratory Medicine at UCSD. They will be joined by Prof. Dr. Anshul Sama Consultant Rhinologist, Dept. of Neurosurgery, Nottingham University Hospital and inventor of daytime NMES for OSA.

The speakers will cover the following topics in this free webinar:
• Mild Obstructive Sleep Apnea: burden of disease and the need for bespoke management
• Emerging technologies and future trends in the management of OSA

The Precision Medicine and Non-Invasive Therapies for Mild Obstructive Sleep Apnea webinar will include a Q&A session with the speakers. Please register HERE.

About Signifier Medical Technologies

Signifier Medical Technologies, previously known as Snoozeal®, is a medical technology company focused on the development and commercialization of innovative and non-invasive solutions for patients with snoring and sleep disordered breathing conditions.

Signifier’s proprietary therapy is the first and only day time genioglossal muscle-neurostimulation technology, with proven clinical data from prestigious and well-recognised universities and academic institutions, that provides a safe and effective treatment for its patients. 1-3

References

1. Wessolleck E, Bernd E, Dockter S, et al. Intraoral electrical muscle stimulation in the treatment of snoring. Somnologie (Berl). 2018; 22 (Suppl 2): 47–52.
2. Sama A, et al. Daytime Intraoral Neurostimulation with Snoozeal® for Treatment of Snoring and Mild Sleep Apnea. CHEST Annual Meeting Notes. 2018.
3. Clinical study of 115 patients with snoring or mild OSA (Apnea- Hypopnea Index (AHI <15). Objective snoring and respiratory parameters were recorded with 2 consecutive WatchPat night sleep studies before and after the use of the device. An intra-oral tongue stimulator (Snoozeal®) device was used for 20mins, once a day for 6-week period

For media enquiries:
info@signifiermedical.com
+44 (0) 207 096 0586

London, United Kingdom

July 17, 2020

Signifier Medical Technologies, an innovator in the sleep-disordered breathing market, is delighted to appoint Matt Sharris as Vice President of Sales in the North American market. Matt will further enhance and strengthen the organization with his wealth of experience and knowledge in the sleep market space.

This appointment follows the company strategy to drive and maximize commercial footprint later into the year in his geography.

Matt Sharris appointed Vice President of Sales – North America

Mr. Sharris appointed as Vice President of Sales for North America who will bring his strategic and commercial experience in respiratory and medical technologies to help guide Signifier Medical Technologies in the commercialization of its eXciteOSA® device in the region.

This will allow the company to generate interest and education within the health care professional community and managing the KOL platform across North America.

Mr. Sharris was most recently Director of Sales and Vice President of Payor Relations for Regional Home Care, with prior roles within account management and sales for ResMed.

Mr. Sharris is based in Boston.

“Today’s announcement further builds upon the Signifier team globally” said Anshul Sama, CMO and Co Founder of Signifier Medical Technologies. “Each person brings extensive medical technologies backgrounds to the business and will help Signifier strengthen channel partnerships, develop strategic alliances and expand our international sales presence.”

About Snoring and OSA

Nearly 1 billion adults aged 30 to 69 are estimated to have obstructive sleep apnea (OSA) globally. There is a strong, clinically proven link between obstructive sleep apnea and co-morbidities like diabetes, hypertension, and strokes. Mild OSA affects over 110 million people in the US and 100 million people in Europe.

Obstructive sleep apnea is marked by recurring collapse of the upper airways during sleep. The most common symptoms are restless sleep, snoring, tiredness during the day, decreased intellectual alertness and personality alterations. Higher risks of cardiovascular diseases and increased mortality rates have been associated with OSA.

Standard therapy of all advanced levels of sleep apnea is with a continuous positive airway pressure (CPAP) device. Many patients find this therapy invasive, and the long-term compliance of CPAP therapy is limited, so there is a demand for new forms of treatment.

About Signifier Medical Technologies

Signifier Medical Technologies, previously known as eXciteOSA®, is a medical technology company focused on the development and commercialization of innovative and non-invasive solutions for patients with snoring and sleep-disordered breathing conditions. Signifier’s proprietary therapy is the first and only daytime genioglossal (tongue) muscle-neurostimulation technology, with proven clinical data from prestigious and well-recognized universities and academic institutions, that provides a safe and effective treatment for its patients.^1-3

For more information, please visit www.snoozeal.com